Trial Profile
A retrospective,cross sectional study to evaluation of the effects of deviations from a regular dosing schedule on glycemic control and hypoglycemia and overweight on patients with Diabetes Mellitus treated with Insulin glargine and Insulin degludec
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2017
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 19 May 2017 New trial record
- 01 Apr 2017 Results published in the Diabetes Therapy